UH's Cristina Rivera Garza is a 2020 MacArthur Fellowship winner. Photo courtesy of John D. & Catherine T. MacArthur Foundation

A prolific fiction writer and award-winning University of Houston academic has just received a major accolade. Distinguished professor Cristina Rivera Garza has been awarded a 2020 MacArthur Fellowship — dubbed more casually as a "genius" grant of a hefty $625,000 — the university announced.

The grant is a no-strings-attached gift "to extraordinarily talented and creative individuals as an investment in their potential," according to the John D. and Catherine T. MacArthur Foundation, which awards the grants each year. Rivera Garza is one of just 21 nationwide individuals to receive the fellowship grant.

Rivera Garza is founder and director of the UH doctoral program in Hispanic Studies with a concentration in creative writing in Spanish.

"This is an incredible — and quite unexpected — honor. I am suddenly short of words," said Rivera Garza in a statement. Amusingly, Rivera Garza told Andrew Dansby of the Houston Chronicle that she didn't take the MacArthur call at first Tuesday morning because she didn't recognize the number. She received an email asking for information about another candidate. "So I finally answered, and they delivered the news. It was quite a shock," she said.

She joins Rick Lowe, a UH professor of art who earned the fellowship in 2014, as the two MacArthur Fellows on faculty at UH. MacArthur Fellowships are among the most prestigious and generous awards given to those who have demonstrated extraordinary talent and dedication in academia, writing, music, film, and other creative fields, UH notes.

The majority of Rivera Garza's creative works are in Spanish but were written in the United States, where she has lived for more than 30 years. She earned her doctorate in Latin American history from the University of Houston in 1995 and was awarded an honorary degree from UH in 2012, according to UH. Rivera Garza joined the University of Houston faculty in 2016 and founded UH's Spanish-language creative writing concentration in 2017. She leads the program as its director.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Intel Corp. and Rice University sign research access agreement

innovation access

Rice University’s Office of Technology Transfer has signed a subscription agreement with California-based Intel Corp., giving the global company access to Rice’s research portfolio and the opportunity to license select patented innovations.

“By partnering with Intel, we are creating opportunities for our research to make a tangible impact in the technology sector,” Patricia Stepp, assistant vice president for technology transfer, said in a news release.

Intel will pay Rice an annual subscription fee to secure the option to evaluate specified Rice-patented technologies, according to the agreement. If Intel chooses to exercise its option rights, it can obtain a license for each selected technology at a fee.

Rice has been a hub for innovation and technology with initiatives like the Rice Biotech Launch Pad, an accelerator focused on expediting the translation of the university’s health and medical technology; RBL LLC, a biotech venture studio in the Texas Medical Center’s Helix Park dedicated to commercializing lifesaving medical technologies from the Launch Pad; and Rice Nexus, an AI-focused "innovation factory" at the Ion.

The university has also inked partnerships with other tech giants in recent months. Rice's OpenStax, a provider of affordable instructional technologies and one of the world’s largest publishers of open educational resources, partnered with Microsoft this summer. Google Public Sector has also teamed up with Rice to launch the Rice AI Venture Accelerator, or RAVA.

“This agreement exemplifies Rice University’s dedication to fostering innovation and accelerating the commercialization of groundbreaking research,” Stepp added in the news release.

Houston team develops low-cost device to treat infants with life-threatening birth defect

infant innovation

A team of engineers and pediatric surgeons led by Rice University’s Rice360 Institute for Global Health Technologies has developed a cost-effective treatment for infants born with gastroschisis, a congenital condition in which intestines and other organs are developed outside of the body.

The condition can be life-threatening in economically disadvantaged regions without access to equipment.

The Rice-developed device, known as SimpleSilo, is “simple, low-cost and locally manufacturable,” according to the university. It consists of a saline bag, oxygen tubing and a commercially available heat sealer, while mimicking the function of commercial silo bags, which are used in high-income countries to protect exposed organs and gently return them into the abdominal cavity gradually.

Generally, a single-use bag can cost between $200 and $300. The alternatives that exist lack structure and require surgical sewing. This is where the SimpleSilo comes in.

“We focused on keeping the design as simple and functional as possible, while still being affordable,” Vanshika Jhonsa said in a news release. “Our hope is that health care providers around the world can adapt the SimpleSilo to their local supplies and specific needs.”

The study was published in the Journal of Pediatric Surgery, and Jhonsa, its first author, also won the 2023 American Pediatric Surgical Association Innovation Award for the project. She is a recent Rice alumna and is currently a medical student at UTHealth Houston.

Bindi Naik-Mathuria, a pediatric surgeon at UTMB Health, served as the corresponding author of the study. Rice undergraduates Shreya Jindal and Shriya Shah, along with Mary Seifu Tirfie, a current Rice360 Global Health Fellow, also worked on the project.

In laboratory tests, the device demonstrated a fluid leakage rate of just 0.02 milliliters per hour, which is comparable to commercial silo bags, and it withstood repeated disinfection while maintaining its structure. In a simulated in vitro test using cow intestines and a mock abdominal wall, SimpleSilo achieved a 50 percent reduction of the intestines into the simulated cavity over three days, also matching the performance of commercial silo bags. The team plans to conduct a formal clinical trial in East Africa.

“Gastroschisis has one of the biggest survival gaps from high-resource settings to low-resource settings, but it doesn’t have to be this way,” Meaghan Bond, lecturer and senior design engineer at Rice360, added in the news release. “We believe the SimpleSilo can help close the survival gap by making treatment accessible and affordable, even in resource-limited settings.”